POET Technologies' leadership is very good at hyping the stock, with two such cases in three weeks. It disclosed a new $5 million contract in the SEC filing that announced Marvell's order cancellation, and headlines ran with a "$500 million" Lumilens order that its own release put at $50 million with potential to scale. It is also oddly letting Lumilens buy deep in-the-money POET warrants at greatly reduced prices, not tied to a 30-day VWAP formula, unlike AMD's OpenAI deal. x.com x.com x.comÂ